Baillie Gifford & Co. Purchases 9,478 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Baillie Gifford & Co. grew its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 175.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 14,876 shares of the company’s stock after purchasing an additional 9,478 shares during the quarter. Baillie Gifford & Co.’s holdings in Medpace were worth $4,966,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Ashton Thomas Securities LLC bought a new stake in shares of Medpace during the 3rd quarter valued at $37,000. J.Safra Asset Management Corp increased its holdings in Medpace by 87.0% in the first quarter. J.Safra Asset Management Corp now owns 101 shares of the company’s stock valued at $41,000 after purchasing an additional 47 shares during the last quarter. DT Investment Partners LLC acquired a new position in Medpace in the second quarter valued at about $41,000. Capital Performance Advisors LLP bought a new position in Medpace during the third quarter worth about $46,000. Finally, Ashton Thomas Private Wealth LLC bought a new position in Medpace during the second quarter worth about $52,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Price Performance

Shares of Medpace stock opened at $361.94 on Thursday. The firm has a market cap of $11.25 billion, a price-to-earnings ratio of 31.69, a price-to-earnings-growth ratio of 2.00 and a beta of 1.37. Medpace Holdings, Inc. has a one year low of $268.80 and a one year high of $459.77. The stock’s 50-day moving average is $341.97 and its 200-day moving average is $376.72.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Monday, October 21st. The company reported $3.01 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.24. Medpace had a return on equity of 50.87% and a net margin of 17.66%. The firm had revenue of $533.32 million during the quarter, compared to the consensus estimate of $540.99 million. During the same quarter in the prior year, the firm posted $2.22 EPS. The business’s revenue was up 8.3% on a year-over-year basis. On average, equities analysts expect that Medpace Holdings, Inc. will post 11.93 EPS for the current year.

Analyst Ratings Changes

MEDP has been the topic of a number of analyst reports. StockNews.com downgraded shares of Medpace from a “buy” rating to a “hold” rating in a research report on Friday, September 27th. Deutsche Bank Aktiengesellschaft reduced their price target on shares of Medpace from $395.00 to $336.00 and set a “hold” rating on the stock in a research report on Wednesday, July 24th. Jefferies Financial Group cut shares of Medpace from a “buy” rating to a “hold” rating and lowered their price objective for the company from $415.00 to $345.00 in a research report on Wednesday, September 25th. Robert W. Baird lowered Medpace from an “outperform” rating to a “neutral” rating and reduced their target price for the stock from $413.00 to $349.00 in a report on Wednesday, October 23rd. Finally, TD Cowen lowered their price target on Medpace from $413.00 to $372.00 and set a “buy” rating for the company in a report on Wednesday, October 23rd. Seven research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, Medpace currently has a consensus rating of “Hold” and an average price target of $380.00.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.